VIVEbiotech expands its manufacturing portfolio with suspension processes for lentiviral vectors
The CDMO adds suspension technology alongside its established adherent process to provide greater flexibility and meet project-specific needs.
VIVEbiotech, a CDMO specialized in the development and manufacturing of lentiviral vectors for advanced therapies, announces the expansion of its manufacturing portfolio with the incorporation of a suspension-based process, complementing its well-established adherent process.
With over 10 years of experience and more than 50 projects delivered for in vivo and ex vivo applications, VIVEbiotech continues to evolve to meet the changing needs of its clients and the gene and cell therapy sector.
“The addition of the suspension process allows us to be more versatile and to offer our clients the flexibility to select the most appropriate technology based on the specific requirements of each project,” says María Echeverría, Head of USP Development at VIVEbiotech.
The company will continue to offer both approaches—adherent and suspension—working either with VIVEbiotech’s adapted cell lines or supporting clients in the adaptation of their own. In all cases, the company’s priority remains unchanged: process flexibility, robustness, and above all, patient safety.
With this expansion, VIVEbiotech further strengthens its commitment to supporting partners from early development through to clinical and commercial manufacturing.
🎥 Watch the video to learn more about this important update and how it strengthens our commitment to advanced therapies.